MHC Class I Presentation – Function & Significance

What Is MHC Class I Presentation?

MHC class I presentation is a fundamental mechanism of the adaptive immune system. MHC stands for Major Histocompatibility Complex. MHC class I molecules are proteins found on the surface of virtually all nucleated cells in the body. Their primary function is to transport short peptide fragments – called antigenic peptides – from inside the cell to the cell surface, where they are displayed to immune cells.

This process enables cytotoxic T cells (also known as CD8⁺ T cells) to "inspect" the contents of a cell without entering it. If a T cell recognizes an abnormal or foreign peptide, it can selectively destroy the affected cell. This is particularly important in viral infections and cancer.

Biological Basis

MHC class I molecules consist of two subunits: the alpha chain (encoded by genes on chromosome 6 within the MHC locus) and beta-2 microglobulin. Together, they form a peptide-binding groove that accommodates peptides typically 8–10 amino acids in length.

In humans, MHC class I molecules are also referred to as HLA class I molecules (HLA = Human Leukocyte Antigen). The key HLA class I genes are HLA-A, HLA-B, and HLA-C. These genes are highly polymorphic, meaning many variants exist across the population, resulting in individual differences in immune responses.

Steps of MHC Class I Antigen Processing and Presentation

The MHC class I presentation pathway consists of several sequential steps:

1. Protein Degradation by the Proteasome

In the cytoplasm, both host and foreign proteins (e.g., viral proteins) are broken down by a large protein complex called the proteasome. Acting like a molecular "shredder," the proteasome cleaves proteins into peptide fragments of approximately 8–10 amino acids in length.

2. Transport into the Endoplasmic Reticulum

The resulting peptides are then shuttled into the endoplasmic reticulum (ER) by dedicated transporter proteins known as TAP proteins (Transporter associated with Antigen Processing), where they are loaded onto newly synthesized MHC class I molecules.

3. Peptide Loading onto MHC Class I Molecules

Within the ER, the peptide-loading complex is assembled. Chaperone proteins including calnexin, calreticulin, and tapasin stabilize the MHC class I molecule and facilitate optimal peptide binding. Only correctly loaded MHC-peptide complexes are released for onward transport.

4. Transport to the Cell Surface

The mature MHC class I–peptide complex is transported via the Golgi apparatus to the cell surface. There, cytotoxic T cells can recognize the complex through their T cell receptor (TCR).

Immunological Significance

MHC class I presentation serves a critical immune surveillance function. It allows the immune system to continuously monitor the protein content of every nucleated cell in the body. This is especially relevant in the following contexts:

• Viral infections: Viruses hijack the host cell machinery to produce viral proteins. These proteins are degraded by the proteasome, presented as peptides on MHC class I molecules, and recognized by cytotoxic T cells, which then destroy the infected cell.
• Cancer: Tumor cells frequently produce altered or overexpressed proteins (tumor-associated antigens). These can be presented via MHC class I molecules and recognized by T cells – a cornerstone of tumor immunology and modern immunotherapy.
• Transplantation medicine: Differences in HLA types between donor and recipient can trigger rejection reactions, as the immune system recognizes foreign MHC molecules as non-self.

Cross-Presentation

A special variant known as cross-presentation allows certain immune cells, particularly dendritic cells, to present extracellularly acquired antigens (normally a hallmark of MHC class II presentation) via MHC class I molecules. This mechanism is critical for immune responses against tumors and certain viruses that do not directly infect dendritic cells.

Clinical Relevance and Therapeutic Applications

Understanding MHC class I presentation has far-reaching clinical implications:

• Vaccine development: Peptide-based vaccines aim to induce MHC class I-restricted cytotoxic T cell responses, for example against viruses or tumors.
• Checkpoint inhibitors: Drugs such as PD-1/PD-L1 inhibitors reactivate exhausted cytotoxic T cells that had previously recognized MHC class I-presented tumor antigens.
• CAR-T cell therapy: Genetically engineered T cells are designed to recognize and eliminate tumor cells more precisely based on their MHC class I-presented antigens.
• Antiviral pharmacogenomics: Knowledge of a patient's HLA type influences drug selection; for example, abacavir in HIV treatment can cause severe hypersensitivity reactions in individuals carrying the HLA-B*57:01 allele.

Comparison with MHC Class II Presentation

In contrast to MHC class I presentation, which occurs on virtually all nucleated cells and activates CD8⁺ cytotoxic T cells, MHC class II presentation is restricted to professional antigen-presenting cells (e.g., dendritic cells, macrophages, B cells). It presents peptides derived from extracellular sources and activates helper T cells (CD4⁺). Both pathways are complementary and essential for a complete adaptive immune response.

References

1. Janeway CA Jr, Travers P, Walport M et al. – Immunobiology: The Immune System in Health and Disease, 9th edition. Garland Science, New York, 2016.
2. Neefjes J, Jongsma ML, Paul P, Bakke O – Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nature Reviews Immunology, 11(12):823–836, 2011. PubMed PMID: 22076556.
3. Blum JS, Wearsch PA, Cresswell P – Pathways of antigen processing. Annual Review of Immunology, 31:443–473, 2013. PubMed PMID: 23298205.